FINASTERIDE
5 ALPHA-REDUCTASE INHIBITORS · BENIGN PROSTATIC HYPERPLASIA WITH LOWER URINARY TRACT SYMPTOM
APHENA PHARMA S
Drug class
5 Alpha-Reductase Inhibitors
5-Alpha-reductase inhibitors are a distinct class of antiandrogenic pharmacotherapies that block the 5-alpha-reductase enzyme responsible for converting testosterone into dihydrotestosterone, a potent androgen involved in tissue growth. Read more about 5 Alpha-Reductase Inhibitors
44 drugs in this class 32 manufacturers
Drugs in 5 Alpha-Reductase Inhibitors
DUTASTERIDE
5 ALPHA-REDUCTASE INHIBITORS · BENIGN PROSTATIC HYPERPLASIA WITH LOWER URINARY TRACT SYMPTOM
XLCARE PHARMACE
HONISTA (minoxidil/finasteride/tretinoin)
ACNE PRODUCTS
SINCERUS FLORID
FINASTERIDE
5 ALPHA-REDUCTASE INHIBITORS · BENIGN PROSTATIC HYPERPLASIA WITH LOWER URINARY TRACT SYMPTOM
EXELAN PHARMACE
JALYN (dutasteride/tamsulosin HCl)
ALPHA-BLOCKERS · BENIGN PROSTATIC HYPERPLASIA WITH LOWER URINARY TRACT SYMPTOM
WAYLIS THERAPEU
FINASTERIDE
5 ALPHA-REDUCTASE INHIBITORS · BENIGN PROSTATIC HYPERPLASIA WITH LOWER URINARY TRACT SYMPTOM
QUALLENT PHARMA
PROSCAR (finasteride)
5 ALPHA-REDUCTASE INHIBITORS · BENIGN PROSTATIC HYPERPLASIA WITH LOWER URINARY TRACT SYMPTOM
PD-RX PHARM
FINASTERIDE
5 ALPHA-REDUCTASE INHIBITORS · BENIGN PROSTATIC HYPERPLASIA WITH LOWER URINARY TRACT SYMPTOM
REMEDYREPACK, I
Filter & compare in the drug finder →
Opens the drug finder with 5 Alpha-Reductase Inhibitors preselected. Add indication or manufacturer filters there.
5-Alpha-reductase inhibitors are a distinct class of antiandrogenic pharmacotherapies that block the 5-alpha-reductase enzyme responsible for converting testosterone into dihydrotestosterone, a potent androgen involved in tissue growth.
By suppressing circulating and tissue levels of dihydrotestosterone, these agents reduce glandular enlargement and limit androgenic stimulation in responsive tissues.
Consequently, the class is primarily indicated for the management of benign prostatic hyperplasia to improve urinary outflow and reduce the need for surgical intervention, as well as for the treatment of androgenetic alopecia to slow hair thinning and promote scalp hair regrowth.
-
nih.gov
5-Alpha-reductase inhibitors are a distinct class of antiandrogenic pharmacotherapies that block the 5-alpha-reductase enzyme responsible for converting testosterone into dihydrotestosterone, a potent androgen involved in tissue growth By suppressing circulating and tissue levels of dihydrotestosterone, these agents reduce glandular enlargement and limit androgenic stimulation in responsive tissues Consequently, the class is primarily indicated for the management of benign prostatic hyperplasia ...
-
nih.gov
5-Alpha-reductase inhibitors are a distinct class of antiandrogenic pharmacotherapies that block the 5-alpha-reductase enzyme responsible for converting testosterone into dihydrotestosterone, a potent androgen involved in tissue growth
-
nih.gov
By suppressing circulating and tissue levels of dihydrotestosterone, these agents reduce glandular enlargement and limit androgenic stimulation in responsive tissues
-
cancer.gov
Consequently, the class is primarily indicated for the management of benign prostatic hyperplasia to improve urinary outflow and reduce the need for surgical intervention, as well as for the treatment of androgenetic alopecia to slow hair thinning and promote scalp hair regrowth
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.